Pfizer (PFE) financial statements

+29.2%since 2007
FY2025 revenue
$62.6B▼ −1.6%
FY2025 net income
$7.8B▼ −3.2%
FY2025 diluted EPS
$1.36▼ −3.5%
FY2025 free cash flow
$9.1B▼ −7.7%

Pfizer income statement

Pfizer income statement
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Revenue62,57963,62759,553
Pretax income7,5208,0231,058
Net income7,7718,0312,119
Diluted earnings per share1.361.410.37

Pfizer balance sheet

Pfizer balance sheet
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Cash and cash equivalents1,1421,1072,917
Total assets208,160213,396226,501
Total liabilities121,385124,899137,213
Total equity86,77588,49789,288
Long-term debt61,64157,40561,538

Pfizer cash flow statement

Pfizer cash flow statement
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Operating cash flow11,70412,7448,700
Capital expenditure-2,629-2,909-3,907
Free cash flow (derived)9,0759,8354,793
Share repurchasesn/a00

Quarterly highlights

Quarterly highlights
USD millionsQ3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025
Period ended27 Sep 202628 Jun 202629 Mar 202631 Dec 2025
Revenue (derived)16,58315,03414,45117,557
Net income (derived)3,242-2482,687-1,648
Diluted earnings per share0.56-0.040.47n/a
Operating cash flow (derived)5,3758352,6155,348
Total assets204,544201,131207,618208,160

Pfizer major shareholders

Pfizer major shareholders
HolderShare of classSharesFiled
Vanguard Capital Management7.5%427,444,8721 May 2026

Pfizer 10-K and SEC filings

Pfizer 10-K and SEC filings
FiledFormTypeDescription
3 November 20268-KCurrent reportCurrent report
3 November 202610-QQuarterly reportQuarterly report
3 November 20268-KCurrent reportCurrent report
4 August 202610-QQuarterly reportQuarterly report
4 August 20268-KCurrent reportCurrent report
18 June 20268-KCurrent reportCurrent report
18 June 20268-KCurrent reportCurrent report
5 May 202610-QQuarterly reportQuarterly report

Common questions

What was Pfizer's revenue in fiscal 2025?

Pfizer reported $62.6 billion in revenue for fiscal 2025, the year ended 31 December 2025, down 1.6% from fiscal 2024.

What was Pfizer's net income in fiscal 2025?

Pfizer reported net income of $7.8 billion for fiscal 2025, the year ended 31 December 2025, down 3.2% from fiscal 2024. Diluted earnings per share were $1.36.

What was Pfizer's free cash flow in fiscal 2025?

Pfizer had $9.1 billion in free cash flow in fiscal 2025. Operating cash flow was $11.7 billion and capital expenditure was $2.6 billion.

What were Pfizer's total assets at the end of fiscal 2025?

Pfizer reported total assets of $208.2 billion at the end of fiscal 2025, the year ended 31 December 2025.

How much Pfizer history do I get?

Every account gets the full history, annual and quarterly, with first reported values and as of dates.